BTIG Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
Tweet Send to a Friend
BTIG analyst Justin Zelin reiterated a Buy rating and $43.00 price target on Syndax Pharmaceuticals (NASDAQ: SNDX).The analyst comments "SNDX ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


